COMPARISON OF MODIFIED RANKIN SCALE AND BARTHEL INDEX IN PATIENTSWITH ISCHEMIC STROKE TREATED WITH INTRAVENOUS THROMBOLYSISCOMPARED WITH NON-SPECIFIC TREATMENT

Abstract

Cerebrovascular diseases, and in particular ischemic stroke, occupy a major place among socially significant diseases due to the associated high incidence, mortality and disability. Intravenous thrombolysis with recombinant tissue plasminogen activator is one of the few approved treatments for acute ischemic stroke. The present study includes two groups of patients with ischemic stroke, treated or not with intravenous thrombolysis, and aims to follow them up to the third month and compare the modified Rankin Scale and Barthel Index Scores. We found less favorable baseline scores in the intravenous thrombolysis group, which improved significantly at the third month. The results support the long-term benefits of intravenous thrombolysis.